ImmuPharma plc (LON:IMM – Get Free Report) shares were up 12.5% on Thursday . The company traded as high as GBX 5.80 ($0.07) and last traded at GBX 5.50 ($0.07). Approximately 19,527,068 shares traded hands during mid-day trading, a decline of 23% from the average daily volume of 25,520,734 shares. The stock had previously closed at GBX 4.89 ($0.06).
ImmuPharma Price Performance
The stock’s 50 day simple moving average is GBX 2.06 and its two-hundred day simple moving average is GBX 1.83. The firm has a market cap of £22.90 million, a P/E ratio of -550.00 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- 3 Stocks to Consider Buying in October
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Financial Services Stocks Investing
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
